Home › Sepsis › NCT07287332
BLOOM: Pragmatic Feasibility Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adults ≥18 years of age * Admitted to one of the ICUs at the study center * Prescribed cefepime therapy by the care team Exclusion Criteria: * Individuals will be those with a cephalosporin allergy * Received \>1 dose of cefepime in the 24 hours before ICU admission * Transferred from an external hospital without compatible EHR * Does not have a cystatin C and a creatinine available for drug dosing * Acute kidney injury stage 2 or higher * Receiving renal replacement therapy * Treated with extracorporeal membrane oxygenation * Undergoing molecular adsorbent recirculating therapy at the time of beta-lactam initiation * Pregnant * Incarcerated * Declined Minnesota research authorization
About the study
The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.
What is being tested
- Up-front individualized dosing algorithm (other)
- Usual Care (other)
Sponsor: Mayo Clinic · Participants: 300 · Started: Jan 15, 2026
Contact the study team
- Gerald W. Flaby Jr., LRT, RRT · Phone: 507-422-3462
Official record on ClinicalTrials.gov — NCT07287332
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.